Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03384433 |
Recruitment Status : Unknown
Verified January 2021 by Leila Dehghani, Isfahan University of Medical Sciences.
Recruitment status was: Recruiting
First Posted : December 27, 2017
Last Update Posted : January 25, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cerebrovascular Disorders | Biological: exosome | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 5 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Safety and Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosome on Disability of Patients With Acute Ischemic Stroke: a Randomized, Single-blind, Placebo-controlled, Phase 1, 2 Trial |
Actual Study Start Date : | April 17, 2019 |
Estimated Primary Completion Date : | June 17, 2021 |
Estimated Study Completion Date : | December 17, 2021 |
Arm | Intervention/treatment |
---|---|
Experimental: exosome or vesicle
CVA patients who have disability, will receive total protein of allogenic MSC-generated exosome transfected by miR-124, one month after attack, via Stereotaxis/Intraparanchymal
|
Biological: exosome
allogenic mesenchymal stem cells derived exosome enriched by miR-124 |
- Incidence of Treatment-Emergent Adverse Events [ Time Frame: 12 months ]deteriorating stroke, stroke recurrences, brain oedema, seizures, hemorrhagic transformation
- measurement of Modified Ranking Scale [ Time Frame: 12 months ]
measure the degree of disability in Stroke patients. score was recorded from 0-6.
0 No symptoms at all
- No significant disability despite symptoms; able to carry out all usual duties and activities
- Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance
- Moderate disability; requiring some help, but able to walk without assistance
- Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance
- Severe disability; bedridden, incontinent and requiring constant nursing care and attention
- Dead
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female acute ischemic patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset.
- Patients with infarct size 3*3
- Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement.
- Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study.
- Patients must have a score on the NIH Stroke Scale 8-24, and mRS ≤ 1
- Women of childbearing age should have a negative pregnancy test performed prior to inclusion
- Obtaining informed consent signed
Exclusion Criteria:
Comatose patients.
- brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage.
- alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis .
- patients with dementia.
- Specify clinical conditions
- Patients who are participating in another clinical trial.
- Inability or unwillingness of individual for giving written informed consent.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03384433
Contact: Masoud Soleimani, Prof | 09122875993 | soleim_m@modares.ac.ir | |
Contact: Leila Dehghani, Assis | 09131363593 | l_dehghani2002@yahoo.com |
Iran, Islamic Republic of | |
Shahid Beheshti University of Medical Sciences | Recruiting |
Tehran, Iran, Islamic Republic of | |
Contact: Leila Dehghani, Dr |
Study Director: | Saeed Oraee-Yazdani, Dr | Shahid Beheshti University of Medical Sciences |
Responsible Party: | Leila Dehghani, Dr Masoud Soleimani, Isfahan University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT03384433 |
Other Study ID Numbers: |
med shahid beheshti university |
First Posted: | December 27, 2017 Key Record Dates |
Last Update Posted: | January 25, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Ischemic Stroke Cerebrovascular Disorders Stroke Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases |